IL1B and macrophage activation syndrome: In conclusion, although first‐line anakinra has been shown to achieve high response rates and minimize glucocorticoid use and thus glucocorticoid‐related side effects in sJIA‐SD in general,6, 9, 11 our study suggests that early initiation of IL‐1 pathway–blocking therapy does not decrease the incidence of MAS.